Literature DB >> 15257414

[Pulmonary hypertension in chronic myeloproliferative disorders].

B M Einsfelder1, K-M Müller.   

Abstract

We report on three autopsy cases with clinical and morphological evidence of pulmonary hypertension and concurrent myeloproliferative disorders. Massive accumulations of pleomorphic, atypical megakaryocytes and thrombotic material are found within the pulmonary capillary beds. Morphometrical studies allowed us to identify on average 1,293.4 (1,145.8-1,401) megakaryocytes per one square centimetre lung tissue (standard value: 25 megakaryocytes/cm(2) lung tissue). The lungs of the controls with unaffected parenchyma show smaller numbers of megakaryocytes. It seems highly unlikely that these haematopoietic cells originate in lung capillaries in the absence of morphological correlates. Recurrent chronic microemboli consisting of megakaryocytes and thrombocytes could be held responsible for the development of secondary chronic pulmonary hypertension. Our observations suggest that pulmonary hypertension associated with chronic myeloproliferative disorders should be classified into the fourth group of the EVIAN-classification of pulmonary hypertension.

Entities:  

Mesh:

Year:  2005        PMID: 15257414     DOI: 10.1007/s00292-004-0709-2

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  18 in total

1.  Platelet production in the pulmonary capillary bed: new ultrastructural evidence for an old concept.

Authors:  D Zucker-Franklin; C S Philipp
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

2.  The incidence, distribution and significance of Megakaryocytes in normal and diseased human tissues.

Authors:  E B SMITH; J BUTCHER
Journal:  Blood       Date:  1952-02       Impact factor: 22.113

3.  Pulmonary platelet production: a physical analogue of mitosis?

Authors:  E A Trowbridge
Journal:  Blood Cells       Date:  1988

4.  The pulmonary vessels as a filter for circulating megakaryocytes in rats.

Authors:  N T Pedersen
Journal:  Scand J Haematol       Date:  1974

5.  [Vascular compartments and distribution of blood volume in the human lung].

Authors:  R Backmann
Journal:  Veroff Morphol Pathol       Date:  1969

6.  Pulmonary hypertension secondary to thrombocytosis in a patient with myeloid metaplasia.

Authors:  K S Marvin; R D Spellberg
Journal:  Chest       Date:  1993-02       Impact factor: 9.410

7.  Pro-megakaryoblasts in bone marrow tissue from patients with primary (idiopathic) osteo-myelofibrosis (agnogenic myeloid metaplasia). An immunomorphometric study on trephine biopsies.

Authors:  J Thiele; S Wagner; H P Bertsch; S Wienhold; R Fischer; D Dienemann; H Stein; R Zankovich
Journal:  Pathol Res Pract       Date:  1990-10       Impact factor: 3.250

8.  Splenic megakaryocytopoiesis in primary (idiopathic) osteomyelofibrosis. An immunohistological and morphometric study with comparison of corresponding bone marrow features.

Authors:  J Thiele; H Klein; S Falk; H P Bertsch; R Fischer; H J Stutte
Journal:  Acta Haematol       Date:  1992       Impact factor: 2.195

9.  Circulating hematopoietic progenitor cells predict survival in patients with myelofibrosis with myeloid metaplasia.

Authors:  Verena Sagaster; Eva Jäger; Ansgar Weltermann; Ilse Schwarzinger; Heinz Gisslinger; Klaus Lechner; Klaus Geissler; Leopold Oehler
Journal:  Haematologica       Date:  2003-11       Impact factor: 9.941

10.  THE PRODUCTION OF BLOOD PLATELETS IN THE LUNGS.

Authors:  W H Howell; D D Donahue
Journal:  J Exp Med       Date:  1937-01-31       Impact factor: 14.307

View more
  2 in total

1.  [Expression of angiotensin I converting enzyme in pulmonary hypertension].

Authors:  A M Müller; M Maas; U Kozianka; F E Franke
Journal:  Pathologe       Date:  2006-03       Impact factor: 1.011

2.  Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders.

Authors:  Ranju Gupta; Sirisha Perumandla; Yelena Patsiornik; Selvanayagam Niranjan; Anju Ohri
Journal:  J Natl Med Assoc       Date:  2006-11       Impact factor: 1.798

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.